Biological E's Corbevax gets DCGI nod as a Heterologous Covid Booster Dose

Current Context: The Hyderabad-based company has come up with a booster dose of Corbevax that increased the neutralizing antibody titers in the Covishield and Covaxin groups significantly when compared to placebo.

• Recently the Drug Controller General of India (DCGI) approved Biological E’s Corbevax and it becomes the first vaccine to get to be used as a heterologous booster for adults who have either received two shots of Covaxin or Covishield.
• As of now, India was using a homologous booster shot for all precaution doses. Now, this become the first heterologous booster for adults.
• Corbevax shot can be booked through the Co-WIN portal by anyone who wished to take a shot.
• Corbevax booster dose provided significant enhancement in immune response and excellent safety profile required for an effective booster.
• Apart from that, it has been claimed that there were no severe or adverse events of interest for 3 months of follow-up after the booster dose was administered.
• Homologous boosters increased neutralizing antibody titers by a factor of 4 to 20, whereas heterologous boosters increased titers by a factor of 6 to 73.

Question:

Q.1 DGCA approved Corbevax Booster is a __________type of booster which is used for adults?
a. Homologous

b. Heterologous
c. Mixed
d. Double strain booster